Noramco Group Announces $25 Million Investment in Halo Pharma’s Whippany Facility for Sterile Injectable Manufacturing
The Noramco Group, a prominent North American provider of integrated Active Pharmaceutical Ingredient (API) and drug product supply chain services, has made a strategic $25 million investment in its Halo Pharma facility located in Whippany, New Jersey. This investment will introduce sterile injectable manufacturing capabilities, including the production of ready-to-use syringes, cartridges, and vials. The move is aimed at addressing critical capacity shortages in the U.S. injectable supply chain and meeting the growing demand from pharmaceutical companies for reliable domestic sterile manufacturing partners.
New Manufacturing Capabilities at Halo Pharma’s Whippany Facility
The investment in Halo Pharma’s Whippany site will primarily involve the installation of a state-of-the-art Groninger UFVN FlexFill line, which is designed for high-speed filling of syringes, cartridges, and vials. This new line will feature cutting-edge technology, including a SKAN isolator, which is essential for enhancing production efficiency while ensuring strict adherence to regulatory compliance standards. The introduction of this equipment will enable the Whippany facility to manufacture batches ranging from 5,000 to 250,000 units, with an annual production capacity exceeding 50 million units.
The facility will begin production with a range of container systems, including 0.5 mL and 1 mL long syringes, 1 mL short syringes, and 2R vials, all in ready-to-fill formats. The filling process can be done using either a peristaltic pump or vacuum methods. As demand grows, additional syringe, cartridge, and vial options will be introduced to meet market needs. The flexibility of the new sterile manufacturing line will significantly enhance Halo Pharma’s ability to support both clinical and commercial-scale projects.
Addressing Critical Supply Chain Needs
Sterile injectables are among the fastest-growing segments in the global pharmaceutical market. However, there is a significant challenge to meet the demand, as many injectable products are still on the FDA’s drug shortage list. This shortage has been compounded by the increased demand for biologics and the pressing needs of the U.S. hospital supply chain. The Noramco Group’s investment in the Whippany facility aims to fill this gap by offering pharmaceutical companies a reliable, North American-based solution for sterile injectable manufacturing.
“This investment is a critical step in addressing the supply chain challenges that the industry faces today,” said Lee Karras, CEO of The Noramco Group. “Our goal is to provide both branded and generic pharmaceutical companies with a reliable, domestic source for sterile injectable manufacturing. This move not only enhances our existing capabilities but also strengthens the resilience of the U.S. pharmaceutical supply chain, particularly in the area of critical drugs.”
Karras also emphasized that the new line would be operational within the next 12 months, ensuring that customers would be supported with high-quality manufacturing capacity. He noted that while the new sterile manufacturing capabilities are an important addition, the Noramco Group remains dedicated to its established expertise in manufacturing APIs, oral solid dose, and liquid dosage forms, which are still integral to meeting the needs of their customers.
Expansion and Renovation of the Whippany Facility
Historically, the Whippany facility has focused on producing oral solid dose (OSD), semi-solid, and liquid formulations for over 20 years. To accommodate the new sterile injectable manufacturing line, significant renovations are planned for the site. These upgrades will ensure that the facility meets the latest standards, including compliance with EU Annex 1 regulations for European market access, while maintaining the rigorous quality standards required for U.S. production.
The sterile filling line will be installed throughout 2025, and the facility will undergo extensive updates to integrate the new technology and infrastructure. The expansion will ensure that the Whippany facility can meet the needs of both current and future customers, providing them with access to the latest innovations in manufacturing technology while maintaining high standards of quality and efficiency.
Strengthening the Noramco Group’s Integrated Services
This investment in sterile injectable manufacturing further strengthens the Noramco Group’s position in the pharmaceutical supply chain. The Group’s ability to offer fully integrated services—ranging from custom API synthesis to drug product development—sets it apart as one of the few companies that can provide end-to-end solutions for pharmaceutical manufacturers.
In addition to the Whippany facility’s upgrades, Noramco’s Purisys business unit in Athens, Georgia, will continue to support the production of new chemical entity (NCE) APIs and generic low bioburden APIs for injectable finished products. This alignment of services ensures that Noramco can offer a comprehensive range of manufacturing solutions to pharmaceutical companies, from the raw materials stage to finished injectable products.
Furthermore, the Noramco Group has plans for additional investments in packaging automation in 2026, further enhancing the efficiency and quality of its manufacturing operations. These ongoing investments are designed to ensure that Noramco remains at the forefront of pharmaceutical manufacturing, providing customers with cutting-edge technology and world-class service.
Looking to the Future: Expanding Capacity to Meet Growing Demand
The $25 million investment in sterile injectable manufacturing capabilities is a direct response to the growing demand for high-quality, domestically produced sterile injectables. As the pharmaceutical market continues to evolve, the need for reliable, scalable manufacturing solutions will only increase. With this investment, Noramco is positioning itself as a key player in the future of injectable manufacturing, ensuring that it can meet the evolving needs of the industry.
The new sterile injectable manufacturing line at the Whippany facility will provide critical capacity to help address ongoing drug shortages, support the U.S. hospital supply chain, and provide a reliable, domestic manufacturing option for pharmaceutical companies. The Noramco Group’s commitment to innovation, efficiency, and quality will ensure that it continues to meet the demands of the rapidly growing sterile injectable market and maintain its leadership in the pharmaceutical manufacturing sector.
In conclusion, this significant investment not only enhances Noramco’s capabilities but also supports the overall goal of strengthening the U.S. pharmaceutical supply chain. By expanding its facilities and capabilities, Noramco is helping to secure the future of sterile injectable manufacturing and addressing the challenges currently faced by the industry.
To explore how the Noramco Group can support your supply needs from APIs to drug products, visit noramco-group.com. To learn more about the new sterile injectable manufacturing capabilities at Halo Pharma’s Whippany, NJ facility, please see Noramco Group executives at DCAT Week (March 17-20, 2025) in New York City.
About The Noramco Group
The Noramco Group was formed to provide a comprehensive, integrated supply chain solution for active pharmaceutical ingredients (APIs) and drug products across North America. Through its companies – Noramco, Purisys, and Halo Pharma – the group provides end-to-end services from clinical development to commercial manufacturing of APIs and drug products. Noramco, based in Wilmington, Delaware, supplies commercial APIs globally and supports various medical treatments, such as pain management and drug abuse treatment. Purisys, located in Athens, Georgia, offers specialized clinical API development and manufacturing services that focus on controlled substances and pharmaceutical reference standards.
Halo Pharma, with operations in Whippany, New Jersey, and Montreal, Quebec, is a contract development and manufacturing organization (CDMO) that provides a wide range of manufacturing services for diverse dosage forms, catering to both brand and generic pharmaceutical clients from development through commercialization. For more information, visit noramco-group.com.
